Effects of beta-blockers on fracture risk

Journal of Musculoskeletal Neuronal Interactions

Volumn 8, Issue 2, 2008, Pages 105-110

  Reid, Ian R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Adrenergic receptors; Osteoblast; Osteoporosis; Sympathetic nervous system

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIHYPERTENSIVE AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; FIBRIC ACID DERIVATIVE; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENALINE; NITRATE; PLACEBO; PROPRANOLOL; THIAZIDE DIURETIC AGENT;

ADRENERGIC SYSTEM; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE TURNOVER; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFECT; FRACTURE; FRAGILITY FRACTURE; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; REVIEW; RISK FACTOR; RISK REDUCTION; VERTEBRA FRACTURE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BONE AND BONES; BONE DENSITY; BONE REMODELING; FRACTURES, BONE; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOPOROSIS; SYMPATHETIC NERVOUS SYSTEM;

EID: 51749103528     PISSN: 11087161     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Imai Y, Rodan SB, Rodan GA. Effects of retinoic acid on alkaline phosphatase messenger ribonucleic acid, catecholamine receptors, and G proteins in ROS 17/2.8 cells. Endocrinology 1988;122:456-63.
2. Rodan SB, Rodan GA. Dexamethasone effects on beta-adrenergic receptors and adenylate cyclase regulatory proteins Gs and Gi in ROS 17/2.8 cells. Endocrinology 1986;118:2510-8.
3. Moore RE. Smith CK II. Bailey CS. Voelkel EF. Tashjian AH Jr. Characterization of beta-adrenergic receptors on rat and human osteoblast-like cells and demonstration that beta-receptor agonists can stimulate bone resorption in organ culture. Bone Miner 1993;23:301-15.
4. Kellenberger S, Muller K, Richener H, Bilbe G. Formoterol and isoproterenol induce c-fos gene expression in osteoblast-like cells by activating beta2-adrenergic receptors. Bone 1998;22:471-8.
5. Kondo A, Mogi M, Koshihara Y, Togari A. Signal transduction system for interleukin-6 and interleukin-11 synthesis stimulated by epinephrine in human osteoblasts and human osteogenic sarcoma cells. Biochem Pharmacol 2001;61:319-26.
6. Takeuchi T, Tsuboi T, Arai M, Togari A. Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. Biochem Pharmacol 2001;61:579-86.
7. Kondo A, Togari A. In vivo stimulation of sympathetic nervous system modulates osteoblastic activity in mouse calvaria. Am J Physiol Endocrinol Metab 2003;285:E661-7.
8. Dietrich JW, Mundy GR, Raisz LG. Inhibition of bone resorption in tissue culture by membrane-stabilizing drugs. Endocrinology 1979;104:1644-8.
9. Pierroz DD, Bouxsein ML, Glatt V, Rizzoli R, Ferrari SL. Intermittent PTH and propranolol have synergistic effects on vertebral trabecular bone in ovariectomized mice. J Bone Miner Res 2004;19:S460.
10. Minkowitz B, Boskey AL, Lane JM, Pearlman HS, Vigorita VJ. Effects of propranolol on bone metabolism in the rat. J Orthop Res 1991;9:869-75.
11. Suzuki A, Palmer G, Bonjour JP, Caverzasio J. Catecholamines stimulate the proliferation and alkaline phosphatase activity of MC3T3-E1 osteoblast-like cells. Bone 1998;23:197-203.
12. Zeman RJ, Hirschman A, Hirschman ML, Guo G, Etlinger JD. Clenbuterol, a beta 2-receptor agonist, reduces net bone loss in denervated hindlimbs. Am J Physiol 1991;261:E285-9.
13. Pataki A, Muller K, Bilbe G, Green JR, Glatt M. Anabolic effects of beta2-agonists, formoterol and salbutamol on cancellous bone of ovariectomized rat. Bone 1996;9:A116.
14. Levasseur R, Sabatier JP, Potrel-Burgot C, Lecoq B, Creveuil C, Marcelli C. Sympathetic nervous system as transmitter of mechanical loading in bone. Joint Bone Spine: Revue du rhumatisme 2003;70:515-9.
15. Cherruau M, Facchinetti P, Baroukh B, Saffar JL. Chemical sympathectomy impairs bone resorption in rats: a role for the sympathetic system on bone metabolism. Bone 1999;25:545-51.
16. Hill EL, Turner R, Elde R. Effects of neonatal sympathectomy and capsaicin treatment on bone remodeling in rats. Neuroscience 1991;44:747-55.
17. Sandhu HS, Herskovits MS, Singh IJ. Effect of surgical sympathectomy on bone remodeling at rat incisor and molar root sockets. Anat Rec 1987;219:32-8.
18. Kukreja SC, Hargis GK, Bowser EN, Henderson WJ, Fisherman EW, Williams GA. Role of adrenergic stimuli in parathyroid hormone secretion in man. J Clin Endocrinol Metab 1975;40:478-81.
19. Schmitt CP, Obry J, Feneberg R, Veldhuis JD, Mehis O, Ritz E, Schaefer F. Beta 1-adrenergic blockade augments pulsatile PTH secretion in humans. J Am Soc Nephrol 2003;14:3245-50.
20. Ke HZ, Xu G, Brault AL. Deletion of the b2 adrenergic receptor prevents bone loss induced by isoproterenol in mice. J Bone Miner Res 2004;19:S3.
21. Pierroz DD, Muzzin P, Glatt V, Bouxsein ML, Rizzoli R, Ferrari SL. b1b2-Adrenergic receptor KO mice have decreased total body and cortical bone mass despite increased trabecular number. J Bone Miner Res 2004;19:S32.
22. Dhillon H, Glatt V, Ferrari SL, Bouxsein ML. b-Adrenergic receptor KO mice have increased bone mass and strength but are not protected from ovariectomy-induced bone loss. J Bone Miner Res 2004;19:S32.
23. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000;100:197-207.
24. Baldock PA, Sainsbury A, Couzens M, Enriquez RF, Thomas GP, Gardiner EM, Herzog H. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002;109:915-21.
25. Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G. Leptin regulates bone formation via the sympathetic nervous system. Cell 2002;111:305-17.
26. Reid IR, Lucas J, Wattle D, Horne A, Bolland M, Gamble GD, Davidson JS, Grey AB. Effects of a beta-blocker on bone turnover in normal postmenopausal women: a randomized controlled trial. J Clin Endocrinol Metab 2005;90:5212-6.
27. Rejnmark L, Vestergaard P, Kassem M, Christoffersen BR, Kolthoff N, Brixen K, Mosekilde L. Fracture risk in perimenopausal women treated with beta-blockers. Calcif Tissue Int 2004;75:365-72.
28. Reid IR, Gamble GD, Grey AB, Black DM, Ensrud KE, Browner WS, Bauer DC. Beta-blocker use, BMD, and fractures in the study of osteoporotic fractures. J Bone Miner Res 2005;20:613-8.
29. Levasseur R, Dargent-Molina P, Sabatier JP, Marcelli C, Breart G. Beta-blocker use, bone mineral density, and fracture risk in older women: results from the Epidemiologie de L'Osteoporose Prospective Study. J Am Geriatr Soc 2005;53:550-2.
30. Bonnet N, Gadois C, McCloskey E, Lemineur G, Lespessailles E, Courteix D, Benhamou CL. Protective effect of beta blockers in postmenopausal women: influence on fractures, bone density, micro and macroarchitecture. Bone 2007;40:1209-16.
31. Jensen J, Nielsen LH, Lyhne N, Hallas J, Brosen K. Drugs and femoral neck fracture: a case control study. J Intern Med 1991;229:29-33.
32. Pasco JA, Henry MJ, Sanders KM, Kotowicz MA, Seeman E, Nicholson GC. beta-adrenergic blockers reduce the risk of fracture partly by increasing bone mineral density: Geelong osteoporosis study. J Bone Miner Res 2004;19:19-24.
33. Rejnmark L, Vestergaard P, Mosekilde L. Treatment with beta-blockers, ACE inhibitors, and calcium-channel blockers is associated with a reduced fracture risk: a nationwide case-control study. J Hypertens 2006:24:581-9.
34. Schlienger RG, Kraenzlin ME, Jick SS, Meier CR. Use of beta-blockers and risk of fractures. JAMA 2004;292:1326-32.
35. de Vries F, Souverein PC, Cooper C, Leufkens HGM, van Staa TP. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and the Netherlands. Calcif Tissue Int 2007;80:69-75.
36. Wiens M, Etminan M, Gill SS, Takkouche B. Effects of anti-hypertensive drug treatments on fracture outcomes: a meta-analysis of observational studies. J Intern Med 2006;260:350-62.
37. Meier CR, Schlienger RG, Kraenzlin ME, Schlegel B, Jick H. HMG-CoA reductase inhibitors and the risk of fractures. JAMA 2000;283:3205-10.
38. Rejnmark L, Vestergaard P, Mosekilde L. Decreased fracture risk in users of organic nitrates: a nationwide case-control study. J Bone Miner Res 2006;21:1811-17.
39. Bolland MJ, Ames RW, Horne AM, Orr-Walker BJ, Gamble GD, Reid IR. The effect of treatment with a thiazide diuretic for 4 years on bone density in normal post-menopausal women. Osteoporos Int 2007;18:479-86.
40. Schoofs MW, Sturkenboom MC, Van Leeuwen JP, Stricker HA. Use of beta-blockers is associated with BMD and fracture risk. Bone 2005;36:S129-30.
41. Gage BF, Birman-Deych E, Radford MJ, Nilasena DS, Binder EF. Risk of osteoporotic fracture in elderly patients taking warfarin - results from the National Registry of Atrial Fibrillation 2. Arch Intern Med 2006;166:241-6.
42. de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW, van Staa TP. Use of beta-2 agonists and risk of hip/femur fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 2007;16:612-9.